Table 4.
Results of univariate and multivariate analysis influencing overall survival
| Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|
| P value | HR | 95% CI | P value | ||
| Age | |||||
| ≥74 | 7 (17.1) | .992 | |||
| <75 | 34 (82.9) | ||||
| PS | |||||
| 1,2 | 7 (17.1) | <.001 | 12.99 | 3.49‐48.35 | <.001 |
| 0 | 34 (82.9) | ||||
| Visceral metastasis | |||||
| Yes | 12 (29.3) | .05 | 2.90 | 1.08‐7.83 | .035 |
| No | 29 (70.7) | ||||
| PSA (ng/mL) | |||||
| >100 | 22 (53.7) | .022 | |||
| ≤100 | 19 (46.3) | ||||
| Hb (mg/dL) | |||||
| ≤11 | 17 (41.5) | .144 | |||
| >11 | 24 (58.5) | ||||
| NLR | |||||
| ≤3.8 | 20 (48.8) | .014 | |||
| >3.8 | 21 (51.2) | ||||
| ALP (U/L) | |||||
| >350 | 16 (39.0) | .09 | |||
| ≤350 | 25 (61.0) | ||||
| Cabazitaxel starting dose (mg/m2) | |||||
| >20 | 27 (65.9) | .053 | |||
| 20 | 14 (34.1) | ||||
| Grade 3/4 neutropenia | |||||
| No | 19 (46.3) | .015 | 4.31 | 1.52‐12.19 | .006 |
| Yes | 22 (53.7) | ||||
ALP, alkaline phosphatase; CI, confidence interval; HR, hazard ratio; NLR, neutrophil‐lymphocyte ratio; PS, performance status; PSA, prostate‐specific antigen.